Date: 13 April 2018
The NIHR IBD BioResource, a national platform for research into inflammatory bowel disease (IBD), has now recruited 10,000 participants.
The NIHR IBD BioResource was established in 2016 to build on knowledge from recent advances in genetics and accelerate the development of new treatments for inflammatory bowel disease.
Inflammatory bowel disease is a term used to describe two conditions: Crohn’s disease and ulcerative colitis. In the UK, more than 300,000 people are affected by Crohn’s disease or ulcerative colitis.
The NIHR IBD BioResource allows researchers to access groups of patients with Crohn’s or colitis who have uniform genetic make-up or clinical features, so that they can ask very focused questions relating to disease mechanisms and potential new treatments.
People who sign up to the NIHR IBD BioResource provide a blood sample and complete a short health questionnaire. They are then contacted about future research projects for which they meet inclusion criteria and asked whether they would like to take part.
Since its launch two years ago, the NIHR IBD BioResource has been rolled out to recruit from 62 hospital sites across the country. Earlier this week it hit the major milestone of 10,000 participants.
Dr Miles Parkes, a consultant gastroenterologist at Cambridge University Hospital and lead for NIHR IBD BioResource, said: “Getting to the 10,000 recruitment mark is a fantastic achievement and I am very grateful to all who have helped to make this possible.
“The NIHR IBD BioResource is a nationwide effort, recruiting people who have Crohn’s disease or ulcerative colitis specifically so that they can help researchers to better understand the causes of inflammatory bowel disease and develop better treatments.”
You may also be interested in